Analytical Data
-
Gene name
RAD51D
- Application
-
Alternative Names
RAD51D；RAD51L3；DNA repair Protein RAD51 homolog 4
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O75771
-
Expression Region
1-328aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MGSMGVLRVG LCPGLTEEMI QLLRSHRIKT VVDLVSADLE EVAQKCGLSY KALVALRRVL LAQFSAFPVN GADLYEELKT STAILSTGIG SLDKLLDAGL YTGEVTEIVG GPGSGKTQVC LCMAANVAHG LQQNVLYVDS NGGLTASRLL QLLQAKTQDE EEQAEALRRI QVVHAFDIFQ MLDVLQELRG TVAQQVTGSS GTVKVVVVDS VTAVVSPLLG GQQREGLALM MQLARELKTL ARDLGMAVVV TNHITRDRDS GRLKPALGRS WSFVPSTRIL LDTIEGAGAS GGRRMACLAK SSRQPTGFQE MVDIGTWGTS EQSATLQGDQ T
-
Molecular Weight
37 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
RAD51D is a crucial protein involved in the repair of DNA double-strand breaks through homologous recombination, a vital process for maintaining genomic stability. Disruptions in this pathway are linked to various cancers, particularly breast and ovarian cancers, where mutations in RAD51D have been associated with hereditary susceptibility. Studies have shown that RAD51D forms nucleoprotein filaments, which play a key role in the search for homologous sequences during DNA repair. Its functionality is closely related to other proteins in the RAD51 family, highlighting its importance in the DNA damage response. Research has demonstrated that loss-of-function mutations in RAD51D lead to impaired DNA repair mechanisms, making cells more prone to genomic instability and oncogenesis. As a significant player in the homologous recombination pathway, RAD51D also serves as a therapeutic target, particularly in the development of PARP inhibitors that exploit the concept of synthetic lethality in tumors with compromised DNA repair capabilities. Understanding the molecular mechanisms governing RAD51D's role in DNA repair not only sheds light on cancer biology but also opens new avenues for targeted therapies in patients with RAD51D-related malignancies. Ongoing investigations focus on characterizing its regulatory networks, interactions with other repair proteins, and the impact of post-translational modifications on its activity, contributing to our understanding of tumorigenesis and potential therapeutic strategies.
